Supply of XOFIGO® (Radium-223 dichloride) Radiopharmaceutical

This contract involves the procurement and delivery of 1,000 units of XOFIGO®, a radiopharmaceutical approved by the FDA for treating metastatic castration-resistant prostate cancer with bone metastases. The product must comply with all applicable federal regulations and adhere to the manufacturer’s specifications, ensuring safety and efficacy for patients. The contract is classified under NAICS code 325412 and is issued by the Department of Veterans Affairs through the 257-NETWORK Contract Office 17. The solicitation for this subcontract was posted on June 1, 2026, with a response deadline of June 8, 2026. Although specific details like the solicitation number, set-aside type, and location of performance are not provided, the contract is clearly focused on supplying this specialized drug to meet medical needs within the federal healthcare system. The emphasis on compliance and FDA approval underscores the critical nature of the product in treating a serious form of prostate cancer.